Implementation of a pathological diagnosis and treatment pathway may improve the molecular detection of lung cancer

Chao Shi; Bing Wei; Xiaohui Liu; Lin Meng; Chengzhi Zhao; Yuxi Chang; Rui Sun; Zhongxian Zhang; Yang Yu; Jie Ma

doi:10.21037/atm-21-6230

Implementation of a pathological diagnosis and treatment pathway may improve the molecular detection of lung cancer

Ann Transl Med. 2022 Jan;10(2):45. doi: 10.21037/atm-21-6230.

Authors

Chao Shi^#^{1

2}, Bing Wei^#^{1

2}, Xiaohui Liu³, Lin Meng³, Chengzhi Zhao^{1

2}, Yuxi Chang^{1

2}, Rui Sun^{1

2}, Zhongxian Zhang⁴, Yang Yu³, Jie Ma^{1

2}

Affiliations

¹ Department of Molecular Pathology, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China.
² Henan Key Laboratory of Molecular Pathology, Zhengzhou, China.
³ Novogene Co., Ltd., Beijing, China.
⁴ Department of Pathology, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China.

^# Contributed equally.

Abstract

Background: The 2018 Guideline from the College of American Pathologists (CAP), the International Association for the Study of Lung Cancer (IASLC), and the Association for Molecular Pathology (AMP) established a benchmark turnaround time (TAT), according to which the results should be available to the treating oncologist within 10 working days. This article focused on the application process of a new protocol for pathological diagnosis and gene testing pathway and a sample collector. We want to solve the problem that there are not enough puncture samples for gene testing, and the benchmark turnaround time of gene detection was long in clinic.

Methods: In this study, we established and validated a new protocol for a pathological diagnosis and treatment pathway that was tested in the Henan Cancer Hospital, China. The "Biology collector (BIOCO)" tool was designed by our team, was made of polyvinyl chloride (PVC) material (patent application number is 201820902335.6). It consisted of two round magnets on the collector that can be adsorbed on the microtome blade holder, thus making it to move arbitrarily. It collected specimens that were discarded when the wax block was trimmed. We analyzed the TAT, testing accuracy and anti-pollution of new protocol based on BIOCO, compared with the conventional process based on the Routine Collection (ROUCO).

Results: The new pathway adopts a parallel approach to conventional pathology and molecular pathology, which significantly shortens the TAT to 4-6 days. The use of the BIOCO tool can effectively save pathological samples, avoid cross-contamination, and reduce the time delay caused by re-sampling. Most importantly, its accuracy and effectiveness are consistent with conventional collection methods.

Conclusions: The new diagnosis and treatment pathway based on the BIOCO collector can be used as a practical approach for the molecular diagnostic platform of the hospital pathology department.

Keywords: New diagnosis pathway; turnaround time (TAT); “BIOCO” collector.